Examples of using Jinarc in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
For the full list of all side effects reported with Jinarc, see the package leaflet.
If you stop taking Jinarc your kidney cysts may grow as fast as they did before you started treatment with Jinarc.
During treatment with Jinarc, your doctor will arrange monthly blood tests to check for changes in your liver function.
Jinarc is for use in patients with normal to moderately reduced kidney function at the beginning of treatment with Jinarc
Jinarc has not been studied in children
Jinarc is used to treat ADPKD in adults with chronic kidney disease(CKD)
Jinarc must not be started in certain patients with increased blood levels of liver enzymes or with signs or symptoms of liver injury.
Jinarc contains the active substance tolvaptan which blocks the effect of vasopressin,
During the first 18 months of treatment, Jinarc can only be supplied to patients whose physician has determined that liver function supports continued therapy.
Jinarc is to be administered twice daily in split dose regimens of 45 mg+ 15 mg, 60 mg+ 30 mg or 90 mg+ 30 mg.
By blocking the effect of vasopressin, Jinarc slows the development of kidney cysts in patients with ADPKD,
The safety and efficacy of Jinarc in CKD stage 5 have not been adequately explored and therefore tolvaptan treatment
Jinarc can only be obtained with a prescription
Blood tests to check the patient's liver function should be performed before starting treatment with Jinarc, and then repeated every month for 18 months and every three months thereafter.
The company that markets Jinarc will provide patients
Prior to launch of Jinarc in each Member State the Marketing Authorisation Holder must agree the content
Jinarc was shown to be effective at slowing down cyst formation in a main study involving 1,445 adults with autosomal dominant polycystic kidney disease who had rapidly progressing disease but normal or moderately reduced kidney function.
Data are not currently available to show whether long-term therapy with Jinarc continues to slow the rate of renal function decline and affect clinical outcomes of ADPKD, including delay in the onset of end-stage renal disease.
Jinarc is contraindicated in patients with elevated liver enzymes and/or signs
bilirubin is required prior to initiation of Jinarc, continuing monthly for 18 months